DocDollars

Mitsubishi Tanabe Pharma Development America, Inc.

NJ · United States · Reporting entity ID 100000191781

Total reported 2019–2025
$19.3M
#329 of 2,960 reporting companies — 0% of all reported industry payments
$329K in general payments across 379 records, plus $19.0M in research funding across 743 records.

How it breaks down

General payments $328,634
Research funding $18,974,740

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Mitsubishi Tanabe Pharma Development America, Inc. reported $19.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #329 of 2,960 reporting companies. 98% of that was research funding and 2% general payments such as consulting, speaking, food and travel. 379 general payment records and 743 research records were filed.

Common questions about Mitsubishi Tanabe Pharma Development America, Inc.

How much has Mitsubishi Tanabe Pharma Development America, Inc. paid US doctors?

Mitsubishi Tanabe Pharma Development America, Inc. reported $19,303,373 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $328,634 in general payments, $18,974,740 in research funding.

How does Mitsubishi Tanabe Pharma Development America, Inc. rank among drug and device companies?

It ranks #329 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Mitsubishi Tanabe Pharma Development America, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.